Distribution of number of AChR-antibody measurements with a corresponding MGFA-score in 67 patients 1983–2013.

<p>Distribution of number of AChR-antibody measurements with a corresponding MGFA-score in 67 patients 1983–2013.</p

Myasthenia Gravis Foundation of America Clinical Classification [18].

<p>Myasthenia Gravis Foundation of America Clinical Classification <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114060#pone.0114060-Jaretzki1" target="_blank">[18]</a>.</p

The effects of AChR-antibody concentration^a) on MGFA classification according to medication group and time since onset based on multiple ordinal logistic regression of 67 MG patients at Haukeland University Hospital, Bergen, Norway from 1983–2013.

<p><i>Abbreviations:</i> AChR: Acetylcholine receptor; MGFA: Myasthenia gravis Foundation of America (1–5); MG: Myasthenia gravis; CI: Confidence interval.</p><p>a)Odds ratio per 100 nmol/L.</p><p>b)Patients treated with pyridostigmine only.</p><p>c)Patients treated with immunosuppressive drugs.</p><p>The effects of AChR-antibody concentration^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0114060#nt107" target="_blank">a)</a>} on MGFA classification according to medication group and time since onset based on multiple ordinal logistic regression of 67 MG patients at Haukeland University Hospital, Bergen, Norway from 1983–2013.</p

Descriptive statistics for MGFA-score (1–5) and AChR-antibody concentration (nmol/L) in each quartile of time since onset for 309 tests of 67 MG patients at Haukeland University Hospital, Bergen, Norway 1983–2013.

<p><i>Abbreviations:</i> MGFA: Myasthenia Gravis Foundation of America; AChR: acetylcholine receptor; MG: Myasthenia gravis; SD: standard deviation.</p><p>a)1st quartile: 0–3 months; 2nd quartile: 3–19 months; 3rd quartile: 19–37 months; 4th quartile: 37 months–21 years.</p><p>Descriptive statistics for MGFA-score (1–5) and AChR-antibody concentration (nmol/L) in each quartile of time since onset for 309 tests of 67 MG patients at Haukeland University Hospital, Bergen, Norway 1983–2013.</p

Demographic statistics at first antibody test of all MG patients (n = 67) with two or more positive AChR-antibody tests registered as living in western Norway 1983–2013 according to immunosuppressive (n = 56) and pyridostigmine (n = 11) therapy.

<p><i>Abbreviations:</i> MG: Myasthenia gravis; SD: standard deviation; AChR: acetylcholine receptor; ab: antibody; MGFA: Myasthenia Gravis Foundation of America; IQR: interquartile range.</p><p>a)Wilcoxon Mann-Whitney test.</p><p>b)Exact chi-square test.</p><p>Demographic statistics at first antibody test of all MG patients (n = 67) with two or more positive AChR-antibody tests registered as living in western Norway 1983–2013 according to immunosuppressive (n = 56) and pyridostigmine (n = 11) therapy.</p

Self-reported diagnosis of ADHD vs. screening positive for ADHD symptoms in the epilepsy group, the reference group without epilepsy, and the group with non-neurological chronic disorders (NNCD).

<p>*Level of significance < 0.001.</p

Percentage and number (n) of individuals with various adverse life events in fathers with epilepsy with and without use of antiepileptic drugs (AEDs) compared to a reference group without epilepsy.

<p>Fathers with non-neurological chronic disorders (NNCD) served as an additional internal control group.</p

Percentage and number (n) of individuals with low self-esteem and low satisfaction with life among fathers with epilepsy with and without use of antiepileptic drugs (AEDs) compared to a reference group without epilepsy.

<p>Fathers with non-neurological chronic disorders (NNCD) served as an additional internal control group.</p

Frequencies for symptoms of ADHD tested with ASRS, previous depression tested with LTMD, current depression tested with SCL_D and current anxiety tested with SCL_A in fathers with epilepsy with and without use of antiepileptic drugs (AEDs) compared to a reference group without epilepsy. Unadjusted p-values and odds ratios (OR) are given for these comparisons. Fathers with non-neurological chronic disorders (NNCD) served as an additional internal control group.

<p>¤ No significant difference between the NNCD versus ‘Epilepsy all’ groups. CI, confidence interval; SD, standard deviation; ASRS, Adult ADHD Self Report Scale; LTMD, Lifetime Major Depression Scale; SCL_D, Hopkins Symptom Check List for current depressive symptoms; SCL_A, Hopkins Symptom Check List for current anxiety symptoms.</p

Conditional analyses of the HLA-A, -B, -C and DRB1 loci (p-values) in early onset myasthenia gravis (EOMG).

<p>P-values are not corrected, p<0.01 is considered significant after correction for multiple comparisons (n = 4).</p